Department of Internal Medicine, AdventHealth Orlando Hospital, Orlando, Florida.
Research Institute, AdventHealth Orlando Hospital, Orlando, Florida.
Transplant Cell Ther. 2021 Aug;27(8):663.e1-663.e6. doi: 10.1016/j.jtct.2021.04.017. Epub 2021 May 2.
The ideal conditioning intensity in allogeneic hematopoietic stem cell transplantation (HSCT) is evolving. Previous prospective studies comparing myeloablative conditioning (MAC) versus reduced-intensity conditioning (RIC) regimens in adults with acute myelogenous leukemia (AML) have shown mixed results. In many of these studies, patients were not stratified based on measurable residual disease (MRD). We evaluated the effect of conditioning intensity on the outcomes of AML patients in complete remission (CR) with flow cytometry evidence of MRD negativity. A total of 135 patients age 20 to 75 years with AML in CR1 or CR2 and flow cytometry evidence of MRD negativity who underwent allogeneic HSCT at our center between 2011 and 2019 were evaluated. We compared overall survival (OS), relapse-free survival (RFS), nonrelapse mortality (NRM), relapse, and acute and chronic graft-versus-host disease (GVHD) in recipients of MAC (n = 89) and RIC (n = 46). Although the patients receiving RIC were older (62 versus 51 years; P < .0001), there were no statistically significant differences between the groups in terms of Eastern Cooperative Oncology Group and European Leukemia Network risk criteria and disease status (CR1 or CR2) at the time of transplantation. At a median follow-up of 24.6 months, no statistically significant differences in OS (hazard ratio [HR], 0.78; 95% confidence interval [CI] 0.42 to 1.42, P = .411) or RFS (HR, 1.004; 95% CI, 0.48 to 2.09, P = .99) were identified. The cumulative incidence of NRM (HR, 0.595; 95% CI, 0.24 to 1.48; P = .2644) and relapse (HR, 1.007; 95% CI, 0.45 to 2.23; P = .9872) was not different between the 2 groups. Grade II-IV and grade III-IV acute GVHD were more frequent in the MAC group (39.3% verses 19.9% [P = .018] and 19.3% versus 2.3% [P < .001], respectively), as was moderate/severe chronic GVHD (23.6% versus 15.8%; P = .038). Our data indicate that conditioning intensity did not appear to affect OS, RFS, NRM, and relapse risk in patients with MRD-negative AML as measured by flow cytometry. RIC resulted in less severe acute and chronic GVHD.
同种异体造血干细胞移植(HSCT)的理想条件强度正在发展。以前比较急性髓系白血病(AML)成人中清髓性 conditioning(MAC)与减量化 conditioning(RIC)方案的前瞻性研究结果不一。在这些研究中,许多患者未根据可测量残留疾病(MRD)进行分层。我们评估了条件强度对 MRD 阴性流式细胞术证据完全缓解(CR)AML 患者结局的影响。在我们中心 2011 年至 2019 年间接受同种异体 HSCT 的年龄在 20 至 75 岁之间、患有 AML 的 135 例 CR1 或 CR2 且有 MRD 阴性流式细胞术证据的患者接受了评估。我们比较了 MAC(n=89)和 RIC(n=46)组患者的总生存率(OS)、无复发生存率(RFS)、非复发死亡率(NRM)、复发以及急性和慢性移植物抗宿主病(GVHD)。尽管接受 RIC 的患者年龄较大(62 岁比 51 岁;P<.0001),但在移植时根据东部肿瘤协作组和欧洲白血病网络风险标准和疾病状态(CR1 或 CR2),两组之间无统计学差异。在中位随访 24.6 个月时,OS(危险比[HR],0.78;95%置信区间[CI],0.42 至 1.42,P=0.411)或 RFS(HR,1.004;95%CI,0.48 至 2.09,P=0.99)无统计学差异。NRM(HR,0.595;95%CI,0.24 至 1.48;P=0.2644)和复发(HR,1.007;95%CI,0.45 至 2.23;P=0.9872)的累积发生率在两组之间无差异。MAC 组更常发生 II-IV 级和 III-IV 级急性 GVHD(39.3%比 19.9%[P=0.018]和 19.3%比 2.3%[P<.001])和中重度慢性 GVHD(23.6%比 15.8%;P=0.038)。我们的数据表明,在 MRD 阴性 AML 患者中,根据流式细胞术测量,条件强度似乎不会影响 OS、RFS、NRM 和复发风险。RIC 导致更轻的急性和慢性 GVHD。